Clinical Trial Update: 12-week Open-label Evaluation of Efficacy and Safety of Indacaterol [Phase 3]

View source ↗

Summary

This 12-week open-label Phase 3 trial evaluated the efficacy and safety of indacaterol in chronic obstructive pulmonary disease and has completed with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Onbrez Breezhaler (indacaterol maleate)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Status: COMPLETED | Results posted: 2013-11-19